8 March 2011 - AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system, which measures central blood pressures and arterial stiffness noninvasively, announced that it has signed a new US$0.6 million agreement to supply SphygmoCor systems and clinical trial support services to a major international pharmaceutical company. Duncan Ross, CEO of AtCor Medical said, “AtCor has converted another contract due to the strength of both SphygmoCor technology and our clinical trial applications and data management services in pharmaceutical trials. We are especially pleased that the assessment of central pressures and arterial stiffness continues to grow beyond hypertension therapies, such as this study, and across disease states as drug companies endeavor to fully characterize the clinical benefits of new and existing drug therapies”. Mr Ross continued “over the past five years there has been mounting evidence of both positive and detrimental effects on central pressures and arterial stiffness in a number of drug classes which has captured the attention of both regulators and the pharmaceutical industry.”... [PDF] AtCor Medical's Press Release -
